Dodge & Cox 13F: Cuts Incyte (INCY) Stake by $108M
Dodge & Cox has reduced its stake in Incyte by 7.6%, as revealed in its latest 13F filing.
Reviewed by automated data checks against the source filing. How we make and check alerts
Dodge & Cox sold 1,009,386 shares from its stake in Incyte Corporation ($INCY), a 7.61% decrease, according to a 13F filing with the SEC dated May 14, 2026. It reported 12,252,356 shares worth $1.31 billion at the end of the quarter.
Since the filing, $INCY is down 0.2% after 1 week, up 4.5% after 1 month and up 15.8% to date (from the $97.63 close on May 14, 2026).
INCY
Incyte Corporation
Key Points
- Dodge & Cox reduced its Incyte stake by 1,009,386 shares, trimming its position by 7.6% to 12,252,356 shares valued at $1.31 billion.
- Incyte stock, trading at $107.31, has a market cap of $21.63 billion and a P/E ratio of 15.27.
- Incyte, a biopharmaceutical company, saw revenue growth of 20.9% with a net margin of 26.7% and ROE of 30.8%.
Get $INCY trade alerts by text
We text you when insiders, Congress or big funds trade $INCY. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Incyte Corporation alert may contain errors. Disclosures
Dodge & Cox has trimmed its position in Incyte Corporation (NasdaqGS: INCY) by over 1 million shares, according to its latest filing with the SEC. The fund reduced its holdings by 1,009,386 shares, bringing its total stake to 12,252,356 shares. This represents a 7.6% decrease in its position, with the current holding valued at approximately $1.31 billion as of May 14, 2026.
What Changed in Dodge & Cox's Incyte Position
Dodge & Cox's recent move saw its Incyte holdings drop from 13,261,742 shares to 12,252,356 shares. The reduction of 1,009,386 shares corresponds to a 7.6% decrease. Despite this trim, the fund still holds a substantial investment in the biopharmaceutical company, valued at about $1.31 billion.
Incyte Corporation Stock Down 14.4%
Shares of Incyte Corporation traded around $107.31. With a market capitalization of $21.63 billion, the company has a P/E ratio of 15.27 and a forward P/E of 11.81. The stock's 52-week range is between $66.74 and $112.29, with a 50-day moving average of $97.51 and a 200-day moving average of $96.38. Incyte maintains a current ratio of 3.68 and a quick ratio of 3.40, with a debt-to-equity ratio of 0.70.
Recent Earnings
Incyte reported revenue of $5.36 billion, reflecting a growth of 20.9%. The company achieved a net margin of 26.7% and a return on equity of 30.8%. The next earnings report is expected on April 28, 2026.
About Incyte
Incyte Corporation is a biopharmaceutical company based in Wilmington, Delaware, focused on discovering and developing therapeutics. The company offers several treatments, including JAKAFI for myelofibrosis and ICLUSIG for leukemia. With a workforce of 2,844 employees, Incyte operates in markets across the United States, Europe, Canada, and Japan. Under the leadership of CEO William J. Meury, the company continues to advance its pipeline of clinical-stage products.
Bottom Line
Dodge & Cox's decision to trim its position in Incyte by over 1 million shares reflects a strategic adjustment in its portfolio. Investors often monitor such moves to gauge institutional sentiment. It's important to note that 13F filings are backward-looking and may not represent the fund's current position. As Incyte continues to perform in the biotech sector, its financial metrics and growth prospects remain a focal point for analysts and investors alike.
Related Filing Alerts
Source: Dodge & Cox's 13F filing on $INCY (May 14, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Dodge & Cox 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts